Results 251 to 260 of about 157,199 (404)

Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome

Brain Pathology, Volume 35, Issue 3, May 2025.
A necrotizing myopathy without a perifascicular pattern is the most common pathological manifestation of anti‐Ha ASS. Abstract To define the clinical, serological, and muscle histopathological characteristics, as well as treatment outcomes, of patients with anti‐Ha antibody.
Bing Zhao, Ying Hou, Kai Shao, XiaoTian Ma, YaPing Yan, Jian‐Qiang Lu, Wei Li, ChuanZhu Yan, LiNing Zhang, TingJun Dai   +9 more
wiley   +1 more source

Commentary on chapter by Klintmalm: Tacrolimus [PDF]

, 1999
Fung, JJ, Starzl, TE
core  

Revisiting the nature and pharmacodynamics of tacrolimus metabolites

Pharmacological Research
The toxicity of tacrolimus metabolites and their potential pharmacodynamic (PD) interactions with tacrolimus might respectively explain the surprising combination of higher toxicity and lower efficacy of tacrolimus despite normal blood concentrations ...
Rudy Mevizou, Hassan Aouad, François-Ludovic Sauvage, Hélène Arnion, Emilie Pinault, Jean-Sébastien Bernard, Gildas Bertho, Nicolas Giraud, Rodolphe Alves de Sousa, Adolfo Lopez-Noriega, Florent Di Meo, Mélanie Campana, Pierre Marquet   +12 more
doaj  

INTERACTION BETWEEN TACROLIMUS AND CHLORAMPHENICOL IN A RENAL TRANSPLANT RECIPIENT

, 1998
Seth L. Schulman, Leslie M. Shaw, Kathy Jabs, Mary B. Leonard, Kenneth L. Brayman   +4 more
openalex   +1 more source

Does tacrolimus cause more severe anemia than cyclosporine A in children after renal transplantation? [PDF]

, 1998
C. Peter, Kay Latta, Dorothee Graf, G. Offner, J. Brodehl   +4 more
openalex   +1 more source

Topical Tacrolimus in the Management of High-Risk Keratoplasty: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Al Khathami A, Alamri RA, Garah RA, Alsamli RS, Alsheikh NB, Alsheikh Alshahrani OB, AlHoshan YS, Alaklabi SM, Benyh SA, Alamri A.   +9 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

POSSIBLE TACROLIMUS ACTION MECHANISMS IN ITS PROTECTOR EFFECTS ON ISCHEMIA-REPERFUSION INJURY

, 1998
Francisco Javier García‐Criado, Francisco S. Lozano-Sanchez, Javier Fernandez-Regalado, J.J. Valdunciel-Garcia, Felipe Carlos Parreño Manchado, Isabel Silva-Benito, Yolanda Zambrano-Cuadrado, Alberto Gómez-Alonso   +7 more
openalex   +1 more source

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation [PDF]

, 1996
Donna Przepiorka, Cindy Ippoliti, Issa F. Khouri, Michael Woo, Rakesh Mehra, D Le Bherz, Sergio Giralt, James Gajewski, Harald E. Fischer, H. A. Fritsche, AB Deisseroth, Karen R. Cleary, R. Champlin, Koen van Besien, Börje Andersson, R Maher, William E. Fitzsimmons   +16 more
openalex   +1 more source

Rare Case of Tacrolimus-Induced Acute Pancreatitis in a Liver Transplant Recipient. [PDF]

ACG Case Rep J
Prado R, Chatterjee A, Zaalishvili Z, Kundu R, Junna S, Sengupta S, Zein N, Mohiuddin SA.   +7 more
europepmc   +1 more source